A
Price
$134.52
Change
+$0.01 (+0.01%)
Updated
Dec 23, 04:59 PM (EDT)
64 days until earnings call
COO
Price
$92.49
Change
-$0.95 (-1.02%)
Updated
Dec 23, 04:59 PM (EDT)
66 days until earnings call
Ad is loading...

A vs COO

Header iconA vs COO Comparison
Open Charts A vs COOBanner chart's image
Agilent Technologies
Price$134.52
Change+$0.01 (+0.01%)
Volume$17.02K
CapitalizationN/A
Cooper Companies (The)
Price$92.49
Change-$0.95 (-1.02%)
Volume$45.54K
CapitalizationN/A
A vs COO Comparison Chart
Loading...
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
COO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
A vs. COO commentary
Dec 24, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Hold and COO is a Hold.

COMPARISON
Comparison
Dec 24, 2024
Stock price -- (A: $134.51 vs. COO: $93.44)
Brand notoriety: A and COO are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: A: 227% vs. COO: 188%
Market capitalization -- A: $42.66B vs. COO: $19.72B
A [@Medical Specialties] is valued at $42.66B. COO’s [@Medical Specialties] market capitalization is $19.72B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

A’s FA Score shows that 1 FA rating(s) are green whileCOO’s FA Score has 0 green FA rating(s).

  • A’s FA Score: 1 green, 4 red.
  • COO’s FA Score: 0 green, 5 red.
According to our system of comparison, A is a better buy in the long-term than COO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

A’s TA Score shows that 5 TA indicator(s) are bullish while COO’s TA Score has 4 bullish TA indicator(s).

  • A’s TA Score: 5 bullish, 6 bearish.
  • COO’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, A is a better buy in the short-term than COO.

Price Growth

A (@Medical Specialties) experienced а -3.23% price change this week, while COO (@Medical Specialties) price change was -1.49% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -0.55%. For the same industry, the average monthly price growth was +0.22%, and the average quarterly price growth was +2.20%.

Reported Earning Dates

A is expected to report earnings on Feb 25, 2025.

COO is expected to report earnings on Feb 27, 2025.

Industries' Descriptions

@Medical Specialties (-0.55% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
A($42.7B) has a higher market cap than COO($19.7B). COO has higher P/E ratio than A: COO (68.09) vs A (34.82). COO YTD gains are higher at: -1.237 vs. A (-2.760). A has higher annual earnings (EBITDA): 1.69B vs. COO (895M). A has less debt than COO: A (2.56B) vs COO (2.77B). A has higher revenues than COO: A (6.74B) vs COO (3.67B).
ACOOA / COO
Capitalization42.7B19.7B217%
EBITDA1.69B895M189%
Gain YTD-2.760-1.237223%
P/E Ratio34.8268.0951%
Revenue6.74B3.67B184%
Total CashN/A135M-
Total Debt2.56B2.77B92%
FUNDAMENTALS RATINGS
A vs COO: Fundamental Ratings
A
COO
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
20
Undervalued
90
Overvalued
PROFIT vs RISK RATING
1..100
4269
SMR RATING
1..100
4383
PRICE GROWTH RATING
1..100
5260
P/E GROWTH RATING
1..100
5786
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

A's Valuation (20) in the Biotechnology industry is significantly better than the same rating for COO (90) in the Medical Specialties industry. This means that A’s stock grew significantly faster than COO’s over the last 12 months.

A's Profit vs Risk Rating (42) in the Biotechnology industry is in the same range as COO (69) in the Medical Specialties industry. This means that A’s stock grew similarly to COO’s over the last 12 months.

A's SMR Rating (43) in the Biotechnology industry is somewhat better than the same rating for COO (83) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than COO’s over the last 12 months.

A's Price Growth Rating (52) in the Biotechnology industry is in the same range as COO (60) in the Medical Specialties industry. This means that A’s stock grew similarly to COO’s over the last 12 months.

A's P/E Growth Rating (57) in the Biotechnology industry is in the same range as COO (86) in the Medical Specialties industry. This means that A’s stock grew similarly to COO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACOO
RSI
ODDS (%)
Bearish Trend 4 days ago
62%
Bullish Trend 4 days ago
63%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
65%
Bullish Trend 4 days ago
60%
Momentum
ODDS (%)
Bearish Trend 4 days ago
52%
Bearish Trend 4 days ago
52%
MACD
ODDS (%)
Bearish Trend 4 days ago
45%
Bearish Trend 4 days ago
51%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
59%
Bearish Trend 4 days ago
57%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
62%
Bearish Trend 4 days ago
58%
Advances
ODDS (%)
Bullish Trend 4 days ago
61%
Bullish Trend 20 days ago
63%
Declines
ODDS (%)
Bearish Trend 6 days ago
58%
Bearish Trend 5 days ago
56%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
68%
Bullish Trend 4 days ago
62%
Aroon
ODDS (%)
Bullish Trend 4 days ago
64%
Bearish Trend 4 days ago
51%
View a ticker or compare two or three
Ad is loading...
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
COO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WD97.751.43
+1.48%
Walker & Dunlop
CAPL21.680.13
+0.60%
CrossAmerica Partners LP
HRL31.680.10
+0.32%
Hormel Foods Corp
MGNX3.18N/A
N/A
MacroGenics
XIN2.27-0.23
-9.20%
Xinyuan Real Estate Co Ltd